Page 103 - 51 the significance--29.2_opt

References
1. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and
type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement
from the American College of Physicians. Ann Intern Med 2007;147(6):417-22.
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical
management of hyperglycemia in type 2 diabetes: a consensus algorithm for the
initiation and adjustment of therapy: a consensus statement of the American
Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care 2009;32(1):193-203.
3. International Diabetes Federation. Guideline for management of post-meal glucose,
2007.
4. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, 3rd, et al.
ACE/AACE consensus conference on the implementation of outpatient manage-
ment of diabetes mellitus: consensus conference recommendations. Endocr Pract
2006;12 Suppl 1:6-12.
5. ADA. Screening for type 2 diabetes. Diabetes Care 2004;27 Suppl 1:S11-14.
6. Landgraf R. [HbA1c – the gold standard in the assessment of diabetes treatment?].

Dtsch Med Wochenschr 2006;131 Suppl 8:S243-6.
7. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, et al. Post-
prandial glucose regulation: new data and new implications. Clin Ther 2005;27
Suppl B:S42-56.
8. Hanefeld M, Bornstein SR, Pistrosch F. Shifting the disease management paradigm
from glucose: what are the cons? Diabetes Care 2009;32 Suppl 2:S353-6.
9. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma
glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:
variations with increasing levels of HbA(1c). Diabetes Care 2003;26(3):881-5.
10. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk
factor for diabetic complications. JAMA 2006;295(14):1707-8.
11. Monnier L, Mas E, Ginet C, et al. Activation of Oxidative Stress by Acute Glucose
Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With
Type 2 Diabetes. JAMA 2006;295(14):1681-1687.
12. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues
with oral antidiabetic agents: Associations with adherence; treatment satisfaction
and health-related quality of life. Diabetes Res Clin Pract;87(2):204-10.
13. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic
effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipi-
demia. Diabetes Care 2005;28(7):1547-1554.
14. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to
type 2 diabetes. Diabetes Care 1997;20(11):1744-66.
15. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
JAMA 2002;287(3):360-72.
16. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Expert Opin Emerg Drugs 2008;13(4):593-607.
17. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide
(exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with
type 2 diabetes. Diabetes Care 2004;27(11):2628-35.
18. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide
(exendin-4) on glycemic control and weight over 30 weeks in metformin-treated
patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100.
19. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects
of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2
diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):
1083-91.
20. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic
control with no weight increase in patients with type 2 diabetes after once-daily
treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211):
a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27(6):
1335-42.
21. Delamater AM. Improving patient adherance. Clinical Diabetes 2006;24(2):71-77.
22. Kurtz SM. Adherence to diabetes regimens: empirical status and clinical applica-
tions. Diabetes Educ 1990;16(1):50-9.

103